1. Home
  2. DKI vs ACXP Comparison

DKI vs ACXP Comparison

Compare DKI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKI

DarkIris Inc. Class A Ordinary Shares

HOLD

Current Price

$5.91

Market Cap

10.1M

Sector

N/A

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.94

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKI
ACXP
Founded
2018
2017
Country
Hong Kong
United States
Employees
19
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
8.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DKI
ACXP
Price
$5.91
$1.94
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
184.9K
103.4K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.29
52 Week High
$11.80
$8.34

Technical Indicators

Market Signals
Indicator
DKI
ACXP
Relative Strength Index (RSI) 71.90 42.73
Support Level $4.82 $1.82
Resistance Level $6.80 $2.30
Average True Range (ATR) 0.80 0.15
MACD 0.03 0.05
Stochastic Oscillator 57.21 46.81

Price Performance

Historical Comparison
DKI
ACXP

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: